PCAS  a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales for the first half of 2017. The PCAS Group had generated consolidated net sales of €110.2 million in the first half of 2017, representing growth of +9.4

Pharmaceutical Synthesis

The Pharmaceutical Synthesis business generated €75.8 million, up +10.5

Fine Specialty Chemicals

Net sales of Fine Specialty Chemicals totaled €34.4 million, up 7.1

Outlook for the current year

The company has confirmed its growth targets for net sales in 2017 and for all its lines of business.